<DOC>
	<DOCNO>NCT03024957</DOCNO>
	<brief_summary>work aim investigate effect intrathecal administration Morphine , Dexmedetomidine combination cellular immunity cytokine production patient undergo major abdominal cancer surgery .</brief_summary>
	<brief_title>Effect Intrathecal Morphine , Dexmedetomidine Both Combination Bupivacaine Immunity</brief_title>
	<detailed_description>Intrathecal ( IT ) adjuvants prolong duration spinal anesthesia postoperative analgesia thereby reduce requirement postoperative supplemental analgesic . The incorporation adjuvant also lower overall dose local anesthetic hence associate side effect . Morphine use widely alleviate various type pain supplement general anesthesia . On hand , morphine report possess immunosuppressive effect . Postoperative immunity also important conjunction defence malignant tumour . Dexmedetomidine highly selective α2 agonist analgesia , sedation , anxiolysis , sympatholysis useful pharmacological action . The extended analgesic efficacy IT dexmedetomidine ( ITD ) postoperative period show clinical study . In addition , current insight identify dexmedetomidine capacity inhibit overproduction variety inflammatory molecule include TNF-α , IL-1β , IL-6 several acute inflammatory animal model .</detailed_description>
	<mesh_term>Bupivacaine</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>ASA III patient schedule major abdominal cancer surgery patient know allergy study drug , significant cardiac , respiratory , renal hepatic disease , drug alcohol abuse , psychiatric illness would interfere perception assessment pain .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>morphine</keyword>
	<keyword>dexmedetomidine</keyword>
	<keyword>immune system</keyword>
</DOC>